Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study

The 5-year update of the randomized phase IIb KEYNOTE-942 study reports long-term outcomes for the individualized mRNA neoantigen vaccine intismeran autogene (mRNA-4157/V940) combined with pembrolizumab versus pembrolizumab alone in patients with completely resected high-risk melanoma. Earlier readouts had demonstrated a clinically meaningful reduction in recurrence risk with the combination, and this update published in the Journal of Clinical Oncology provides critical durability data for the first personalized mRNA cancer vaccine to reach advanced clinical testing. The results are pivotal to the design of the ongoing confirmatory phase III INTerpath-004 trial and to the broader development of individualized neoantigen therapy.